TPF方案诱导化疗后放疗联合尼妥珠单抗同期治疗局部晚期鼻咽癌研究  

Clinical study of TPF induction chemotherapy plus radiotherapy combined with Nimotuzumab in the treatment of locoregionally advanced nasopharyngeal carcinoma

作　　者：柯柳杨[1] 朱的霞 梁文胜[1] 沈冰 Ke Liuyang;Zhu Dixia;Liang Wensheng;Shen Bing(Department of Radiatherapy,Central Hospital of Guangdong Nongken,Zhanjiang 524000,China)

机构地区：[1]广东省农垦中心医院放疗二区,湛江524002

出　　处：《中华转移性肿瘤杂志》2022年第2期153-157,共5页Chinese Journal of Metastatic Cancer

基　　金：湛江市2019年第二批非资助科技攻关计划项目(2019B01095)。

摘　　要：目的观察多西他赛+顺铂+氟尿嘧啶(TPF)方案诱导化疗后放疗联合尼妥珠单抗靶向治疗局部晚期鼻咽癌近期疗效及不良反应。方法将80例Ⅲ-Ⅳa期鼻咽癌患者随机均分为试验组和对照组,两组患者均先行3个周期TPF方案诱导化疗。诱导化疗后试验组予容积调强弧形治疗(VMAT)联合尼妥珠单抗靶向治疗,对照组予VMAT联合奈达铂同期化疗。结果治疗结束后3个月疗效评价,试验组完全缓解(CR)率为85%(34/40),部分缓解(PR)率为7%(3/40);对照组CR率为93%(37/40),PR率为5%(2/40)(P=0.608)。试验组在消化道反应、血小板减少症、肝功能损伤方面的发生率明显低于对照组(P=0.025、0.030、0.034)。结论VMAT联合尼妥珠单抗治疗局部晚期鼻咽癌与同期放化疗相比有相似疗效,但不良反应更低。Objective To evaluate the efficacy and side effects of TPF induction chemotherapy plus radiotherapy combined with Nimotuzumab in the treatment of locoregionally advanced nasopharyngeal carcinoma.Methods 80 Patients with locoregionally advanced nasopharyngeal carcinoma(Ⅲ,Ⅳa)were randomly divided into study group and control group.All patients received TPF induction chemotherapy for 3 cycles with a 21 day interval.The study group was treated with Nimotuzumab plus volumetric modulated arc therapy(VMAT).The patients were treated with simultaneous VMAT and Nedaplatin concurrent chemoradiotherapy.Results Efficacy evaluation at 3 months after completion of treatment,The complete remission rate was 85%(34/40),partial remission rate was 7%(3/40)in study group;and with 93%(37/40),5%(2/40)in control group(P=0.608).The gastrointestinal reaction,thrombocyte penia and liver and kidney damage in study group were significantly lower than those in control group(P=0.025,P=0.030 and P=0.034).Conclusions Nimotuzumab combined with volumetric intensity-modulated arc therapy has a good effect and less side effects in the treatment of locoregionally advanced nasopharyngeal carcinoma.

关 键 词：鼻咽癌 容积调强弧形治疗 尼妥珠单抗 奈达铂 治疗结果 不良反应 

分 类 号：R739.63[医药卫生—肿瘤]